Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Melanoma
NCT02180061Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2014
- Primary completion
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of pembrolizumab in cutaneous melanoma (CM) and mucosal melanoma (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing Adverse Events, Number of Participants Discontinuing Treatment Due to AEs up to 24 months and 1 more. Started Jul 2014; status: completed.
02
Drugs
03
Conditions
cutaneous melanoma (CM)mucosal melanoma
Beyond the preview
Go deeper on NCT02180061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02180061.